Severity of ICU-acquired pneumonia according to infectious microorganisms

Pierre Damas, Nathalie Layios, Laurence Seidel, Monique Nys, Pierrette Melin, Didier Ledoux, Pierre Damas, Nathalie Layios, Laurence Seidel, Monique Nys, Pierrette Melin, Didier Ledoux

Abstract

Purpose: To assess the severity of intensive care unit (ICU)-acquired pneumonia (ICUAP) according to the bacteria involved, classified into seven groups: third-generation cephalosporin-resistant non-fermenting Gram-negative bacilli (resistant C3NF); sensitive C3NF; methicillin-resistant Staphylococcus aureus; methicillin-sensitive Staphylococcus aureus; extended-spectrum beta-lactamase-producing Enterobacteriaceae; Enterobacteriaceae not producing extended-spectrum beta-lactamase; Haemophilus influenzae and Streptococcus pneumoniae.

Methods: Over a 4-year period, sequential organ failure assessment (SOFA) score was prospectively measured daily in 453 adult patients with ICUAP. ICUAP severity was evaluated by the severity of sepsis and by the occurrence of new organ dysfunctions or failures (OD/F) during ICUAP.

Results: Septic shock occurred in 21% of all cases of ICUAP. The occurrence of new OD/F during ICUAP was similar regardless of the identified microorganism. These new OD/F represented less than 11% of SOFAmax, defined as the sum of all OD/F occurring at any time during the ICU stay. There was a significant association between SOFApreICUAP, defined as the sum of all the OD/F occurring before ICUAP, and ICUAP severity. In the multivariate analysis, the type of bacteria was not a risk factor (RF) for occurrence of septic shock and mortality. Age and SOFApreICUAP were RF for the sepsis severity. The ICUAP severity was an RF for ICU mortality.

Conclusions: ICUAP was responsible for a minor proportion of OD/F occurring during the ICU stay. Severity of ICUAP was related to clinical status prior to ICUAP, but not to the type of bacteria. ICU mortality depended on the severity of ICUAP.

References

    1. JAMA. 1995 Aug 23-30;274(8):639-44
    1. J Antimicrob Chemother. 2000 Aug;46(2):327-8
    1. Am J Respir Crit Care Med. 2003 Jul 1;168(1):77-84
    1. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
    1. Intensive Care Med. 2008 May;34(5):856-64
    1. Intensive Care Med. 2003 Nov;29(11):2086-9
    1. Crit Care Med. 2006 Feb;34(2):344-53
    1. Am Rev Respir Dis. 1990 Sep;142(3):523-8
    1. Crit Care Med. 2009 Jan;37(1):291-304
    1. Am J Respir Crit Care Med. 2010 Oct 1;182(7):910-7
    1. JAMA. 2003 Nov 19;290(19):2588-98
    1. Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903
    1. Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S93-9
    1. Intensive Care Med. 2004 Apr;30(4):580-8
    1. Crit Care Med. 2008 Mar;36(3):964-6
    1. Crit Care Med. 1992 Jun;20(6):864-74
    1. J Trauma. 2010 Oct;69(4):849-54
    1. Chest. 2008 Dec;134(6):1208-1216
    1. Intensive Care Med. 2010 May;36(5):781-9
    1. Am J Med. 1993 Mar;94(3):281-8
    1. Curr Opin Infect Dis. 2008 Apr;21(2):174-8
    1. Crit Care. 2009;13(5):315
    1. JAMA. 1996 Mar 20;275(11):866-9
    1. Crit Care Med. 2009 Oct;37(10):2709-18
    1. Chest. 1995 Dec;108(6):1655-62
    1. Intensive Care Med. 2003 Dec;29(12):2170-2173
    1. Intensive Care Med. 2002 Feb;28(2):108-21
    1. Ann Intern Med. 1995 May 15;122(10):743-8
    1. Intensive Care Med. 1996 Jul;22(7):707-10
    1. Intensive Care Med. 1999 Jul;25(7):686-96
    1. JAMA. 1993 Dec 22-29;270(24):2957-63
    1. N Engl J Med. 2006 Dec 21;355(25):2619-30

Source: PubMed

3
Prenumerera